238 related articles for article (PubMed ID: 11078491)
1. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials.
Manola J; Atkins M; Ibrahim J; Kirkwood J
J Clin Oncol; 2000 Nov; 18(22):3782-93. PubMed ID: 11078491
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experience.
Nicholas MN; Khoja L; Atenafu EG; Hogg D; Quirt I; Butler M; Joshua AM
Melanoma Res; 2018 Dec; 28(6):571-577. PubMed ID: 30067547
[TBL] [Abstract][Full Text] [Related]
3. Prognostic score for patients with advanced melanoma treated with ipilimumab.
Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
5. Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab.
Valpione S; Martinoli C; Fava P; Mocellin S; Campana LG; Quaglino P; Ferrucci PF; Pigozzo J; Astrua C; Testori A; Chiarion-Sileni V
Eur J Cancer; 2015 Sep; 51(14):2086-94. PubMed ID: 26227432
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for survival of patients treated systemically for disseminated melanoma.
Eton O; Legha SS; Moon TE; Buzaid AC; Papadopoulos NE; Plager C; Burgess AM; Bedikian AY; Ring S; Dong Q; Glassman AB; Balch CM; Benjamin RS
J Clin Oncol; 1998 Mar; 16(3):1103-11. PubMed ID: 9508197
[TBL] [Abstract][Full Text] [Related]
7. A prognostic model and staging for metastatic uveal melanoma.
Eskelin S; Pyrhönen S; Hahka-Kemppinen M; Tuomaala S; Kivelä T
Cancer; 2003 Jan; 97(2):465-75. PubMed ID: 12518371
[TBL] [Abstract][Full Text] [Related]
8. Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanoma.
Flaherty LE; Liu PY; Unger J; Sondak VK
Am J Clin Oncol; 1997 Dec; 20(6):600-4. PubMed ID: 9391549
[TBL] [Abstract][Full Text] [Related]
9. Real-world outcomes of advanced melanoma patients not represented in phase III trials.
van Zeijl MCT; Ismail RK; de Wreede LC; van den Eertwegh AJM; de Boer A; van Dartel M; Hilarius DL; Aarts MJB; van den Berkmortel FWPJ; Boers-Sonderen MJ; de Groot JB; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; Haanen JBAG; Wouters MWJM
Int J Cancer; 2020 Dec; 147(12):3461-3470. PubMed ID: 32559817
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in 1,521 melanoma patients with distant metastases.
Barth A; Wanek LA; Morton DL
J Am Coll Surg; 1995 Sep; 181(3):193-201. PubMed ID: 7670677
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors in metastatic melanoma.
Ryan L; Kramar A; Borden E
Cancer; 1993 May; 71(10):2995-3005. PubMed ID: 8490827
[TBL] [Abstract][Full Text] [Related]
13. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.
Keilholz U; Conradt C; Legha SS; Khayat D; Scheibenbogen C; Thatcher N; Goey SH; Gore M; Dorval T; Hancock B; Punt CJ; Dummer R; Avril MF; Bröcker EB; Benhammouda A; Eggermont AM; Pritsch M
J Clin Oncol; 1998 Sep; 16(9):2921-9. PubMed ID: 9738559
[TBL] [Abstract][Full Text] [Related]
14. New prognostic index to predict survival in patients with cancer of unknown primary site with unfavourable prognosis.
Trivanović D; Petkovic M; Stimac D
Clin Oncol (R Coll Radiol); 2009 Feb; 21(1):43-8. PubMed ID: 18976894
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma.
Bedikian AY; Johnson MM; Warneke CL; Papadopoulos NE; Kim K; Hwu WJ; McIntyre S; Hwu P
Cancer Invest; 2008 Jul; 26(6):624-33. PubMed ID: 18584354
[TBL] [Abstract][Full Text] [Related]
16. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model.
Schmidt H; Bastholt L; Geertsen P; Christensen IJ; Larsen S; Gehl J; von der Maase H
Br J Cancer; 2005 Aug; 93(3):273-8. PubMed ID: 16052222
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for survival after enucleation for choroidal and ciliary body melanomas.
Isager P; Ehlers N; Overgaard J
Acta Ophthalmol Scand; 2004 Oct; 82(5):517-25. PubMed ID: 15453846
[TBL] [Abstract][Full Text] [Related]
18. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
Wakelee HA; Bernardo P; Johnson DH; Schiller JH
Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941.
Escudier B; Choueiri TK; Oudard S; Szczylik C; Négrier S; Ravaud A; Chevreau C; Venner P; Champagne P; Croteau D; Dupont E; Hariton C; Bukowski RM
J Urol; 2007 Nov; 178(5):1901-5. PubMed ID: 17868728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
